Dr. Catherine Chappell
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Texas Southwestern Medical School at Dallas
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
PA license MD442077 -
Addiction Medicine (Internal Medicine) Physician
PA license MD442077
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 3 companies reported 15 payments worth $19,080 in total to this clinician.
| Gilead Sciences, Inc. | $19,024 |
|---|---|
| Merck Sharp & Dohme LLC | $32.35 |
| AbbVie Inc. | $23.34 |
| Consulting Fee | $17,118 |
|---|---|
| Travel and Lodging | $1,368 |
| Food and Beverage | $594 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 31, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $12,618 |
| Gilead Sciences, Inc. Apr 16, 2025 | Consulting Fee Biktarvy · HIV Company’s description;4286240;VEM US;10108628 | $4,500 |
| Gilead Sciences, Inc. Apr 4, 2025 | Travel and Lodging Biktarvy · HIV · travel to Austin, TX · in-kind Company’s description;4286179;VEM US;10108628 | $973 |
| Gilead Sciences, Inc. Apr 4, 2025 | Travel and Lodging Biktarvy · HIV · travel to Austin, TX · in-kind Company’s description;4286229;VEM US;10108628 | $395 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $557,502 in research payments for these studies, mostly to the institutions running them.
- Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC)
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.